
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Explore how type 2 inflammation drives the production of FeNO in severe asthma

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Join Dr. Miguel Lanz as he explains, in Spanish, the clinical utility of FeNO as a biomarker in severe asthma.
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.
Join Professors Brusselle and Backer as they discuss the concept of disease modification in asthma.
Explore how type 2 inflammation drives the production of IgE in severe asthma

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.